Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
Crossref DOI link: https://doi.org/10.1007/s00280-015-2680-4
Published Online: 2015-01-20
Published Print: 2015-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Liu, Ying
Ren, Zhonghai
Xu, Shuning
Bai, Hua
Ma, Ning
Wang, Feng
License valid from 2015-01-20